Capricor Therapeutics faces shareholder deadline pressure as class action lawsuit over alleged securities fraud progresses
Executive summary: ClaimsFiler issued a shareholder alert on August 7, 2026, reminding investors with losses over $100,000 that they have until September 28, 2026, to apply for lead plaintiff status in a securities class action lawsuit against Capricor Therapeutics (CAPR). The lawsuit centers on allegations that Capricor misled investors about the efficacy of its drug Deramiocel and the integrity of clinical data, contributing to a reported 64% stock drop earlier in August 2026, with ongoing legal exposure and potential financial liability.
Who is involved: Key parties include Capricor Therapeutics, Inc. (NASDAQ: CAPR), the law firms Robbins Geller Rudman & Dowd LLP, Hagens Berman, Levi & Korsinsky, and SueWallSt, along with affected investors who traded CAPR securities between December 17, 2025, and July 26, 2026.
Likely next: Investors must submit lead plaintiff applications by September 28, 2026; after that, the court will appoint a lead plaintiff, and the case will proceed through discovery, with potential settlement or trial depending on evidence and negotiations.
ClaimsFiler has reminded investors with losses exceeding $100,000 that they must file lead plaintiff applications by September 28, 2026, in a securities class action lawsuit against Capricor Therapeutics, Inc. The lawsuit alleges the company misrepresented the statistical significance of its Phase 3 HOPE-3 trial results for Deramiocel while allegedly omitting that the final analysis plan was altered one day before unblinding without FDA agreement. This follows a pattern of repeated investor alerts since early August 2026 regarding the same litigation, indicating sustained legal and reputational pressure on the biotech firm.
Timeline
- — Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR (PR Newswire)
- — INVESTOR NOTICE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - CAPR (PR Newswire)
- — SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR (PR Newswire)
- — CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors (PR Newswire)
Analysis — what this means
Likely next events
- Lead plaintiff application deadline: September 28, 2026
- Court appointment of lead plaintiff: expected October 2026
- Discovery phase to begin: Q4 2026
- Potential settlement or motion rulings: H1 2027
Sectors affected
- Biotechnology
- Pharmaceuticals
- Regenerative medicine
- Clinical trial reporting
Regulatory implications
- FDA scrutiny over clinical trial protocol changes and disclosure obligations
- SEC enforcement potential under Sections 10(b) and 20(a) of the Exchange Act
- Increased focus on pre-unblinding statistical analysis plan amendments in biotech disclosures
Historical parallels
- Sarepta Therapeutics SEC settlement (2020) over misleading Duchenne muscular dystrophy trial data
- Amarin Corporation securities litigation (2018) regarding Vascepa trial outcome disclosures
- Vertex Pharmaceuticals shareholder lawsuits (2021) related to cystic fibrosis trial data transparency
Key entities
Sources
Open the full interactive case file on Beyond →